Benzinga | Aug 20, 2021 06:41AM EDT

SVB Leerink Maintains Outperform on AbbVie, Raises Price Target to $148

SVB Leerink analyst Geoffrey Porges maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $145 to $148.